TSHA Stock Analysis: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$5.84
-0.03 (-0.43%)
▼
5d:
+5.32%
30d:
-10.64%
90d:
-7.82%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Smart Money Accumulation
None View Scanner →
Strength: 8.9/10
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TSHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TSHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $5.83, which is considered slightly low relative to its 30-day fair value range of $5.61 to $6.47.
Technical Outlook: Technically, TSHA is in a uptrend. The price is approaching resistance at $5.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TSHA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.15 (+124.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TSHA is in a uptrend. The price is approaching resistance at $5.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TSHA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.15 (+124.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.61 -
$6.47
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 124.5% below Wall St target ($13.15)
Trading Range Analysis
30-Day Trading Range
$5.61 -
$6.47
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.28
Resistance Level
$5.98
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.47
Wall Street Target
$13.15
(+124.5%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: August 03, 2026 1:55 PM ET
Data refreshes hourly during market hours. Next update: 2:55 PM
Data refreshes hourly during market hours. Next update: 2:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sukumar Nagendran
SELL
200000 shares
2026-04-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
